Company / Revenue
Lilly (Eli) Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$65.2B
FY2025
5-year range
$22.3B / $65.2B
FY2021-FY2025
Trend
+44.7%
vs FY2024
Sector context
#2 of 155
Health Care
What the data says
Among 155 Health Care companies, Lilly (Eli) is in the top 1% for revenue. Revenue has increased for 5 consecutive years, from $21.5B in FY2020 to $65.2B in FY2025.
Based on SEC 10-K filings.
$65.2B in FY2025 with a 5-year CAGR of +24.8%. Ranks 2nd among 155 companies in Health Care.
Improved from $28.3B to $65.2B over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +38.5%
- 5-Year CAGR
- +24.8%
- 10-Year CAGR
- -
Sector benchmark
Top 1% in Health CareTop 1% of 155This company $65.2B Sector average $4.5B
▼
+1357.9% above sector average
Key checks
Key Insights
- Lilly (Eli)'s revenue has grown for 5 consecutive years.
- 5-year CAGR of +24.8%, indicating consistent growth.
- In FY2025, revenue increased 44.7% year-over-year.
- Ranks #2 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.02 (distress zone, below 1.8 threshold)
- Strong profit margin: 31.0%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 77.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $65.2B | +44.7% |
| FY2024 | $45.0B | +59.1% |
| FY2023 | $28.3B | +15.4% |
| FY2022 | $24.5B | +9.9% |
| FY2021 | $22.3B | +3.8% |
| FY2020 | $21.5B | -3.7% |
| FY2019 | $22.3B | +3.8% |
| FY2018 | $21.5B | +7.7% |
| FY2017 | $20.0B | -6.0% |
| FY2016 | $21.2B | +6.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026